IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • Global Web Directory
  • Drugs
Biotechnology
Diagnostic Substances
Drug Delivery
Drug Manufacturers - Major
Drug Manufacturers - Other
Drug Related Products
Drugs - Generic

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated company was founded in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. The Company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Corcept's principal product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor.

SEQUENOM, Inc.

SEQUENOM, Inc.

SEQUENOM, Inc. company was founded in 1994 and is headquartered in San Diego, California with additional offices in Queensland, Australia; Beijing, China; and Newton, Massachusetts. Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations. The company offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. Sequenom also provides the iPLEX multiplexing assay reagents and chips, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. In addition, the company engages in the research, development, and the commercialization of various non-invasive molecular diagnostic tests for prenatal genetic disorders and diseases, oncology, and infectious diseases. It offers its products through direct sales and support personnel to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and government agencies worldwide. Sequenom has a collaboration agreement with the Immune Tolerance Institute to develop an advanced newborn screening test for severe combined immunodeficiency.

Alizyme plc

Alizyme plc

Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them. It targets conditions prevalent primarily in industrialized countries, including obesity, type 2 diabetes (often associated with obesity), and ulcerative colitis. Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.

Fornix BioSciences N.V.

Fornix BioSciences N.V.

Fornix was established in 1999 after a reverse takeover of Dr. Fisher Farma B.V. by Artu Biologicals. Fornix BioSciences has joined the draft in the war against allergies. The Dutch company develops diagnostic and immunotherapeutic allergen products and medical aids. Its allergy division develops and markets sublingual (under the tongue) allergen aids to human and animal patients, particularly dogs, throughout Europe. The company's trading division, Dr. Fisher Farma, imports and distributes a variety of patented drugs, while its Medical Aids division focuses on the sale of medical aids and medical and nursing disposables.

Peplin, Inc.

Peplin, Inc.

Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

Ikonisys Inc.

Ikonisys Inc.

Ikonisys is developing diagnostic tests for oncology and prenatal applications. Its lead product, fastFISH is a series of kits that help in identifying various prenatal conditions. FastFISH amnio is approved for identifying the chromosomal characteristics of birth defects such as Down syndrome, Edward's syndrome, and Patau syndrome. The company's oncoFish product line includes an FDA approved test for bladder cancer. The company is also developing a product can find chromosomal abnormalities in a fetus by testing the mother's blood, reducing the dangers associated with the standard, but invasive, amniocentesis procedure.

CombinatoRx, Incorporated

CombinatoRx, Incorporated

CombinatoRx, Incorporated company was founded in 2000 and is based in Cambridge, Massachusetts. CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. In December 2009, CombinatoRx and Neuromed Pharmaceuticals Inc. announced that they have merged.

Lorus Therapeutics Inc.

Lorus Therapeutics Inc.

Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.

Otsuka Pharmaceutical Europe Ltd.

Otsuka Pharmaceutical Europe Ltd.

Otsuka Pharmaceutical Europe was founded in 1998. Otsuka Pharmaceutical Europe markets drugs and health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. The company also conducts research and development of pharmaceuticals, focusing on the fields of gastroenterology, neurology, ophthalmology, and the cardiovascular system. Marketed drugs include schizophrenia treatment Abilify (through a partnership with Bristol-Myers Squibb), Adacolumn for inflammatory bowel disease, Mikelan for ocular glaucoma and hypertension, Pletal for peripheral vascular disease, and UBiT for gastrointestinal infection diagnosis.

Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company’s proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The company’s principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007.

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
SC asks Allahabad HC not to proceed with DA case against Rahul Gandhi
IndiaCatalog News
Sebi launches portals to strengthen cybersecurity incident reporting
IndiaCatalog News
NSE seeking valuation of as much as ₹5.26 trillion in planned IPO
IndiaCatalog News
Pakistan top court orders former PM Imran Khan to be shifted to hospital
IndiaCatalog News
Govt to set up high-level banking committee very soon: Sitharaman

CORPORATE NEWS

Amazon India
Amazon India
Siemens Limited
Siemens Limited
Ford India Limited
Ford India Limited
National Stock Exchange of India Ltd (NSE)
National Stock Exchange of India Ltd (NSE)
ICICI Bank
ICICI Bank
Bajaj Auto Limited
Bajaj Auto Limited
Essar Power Ltd.
Essar Power Ltd.
Apollo Hospitals
Apollo Hospitals
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com